Get started
Work

Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Year: 2017
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs16-p4-22-15
Authors: A Bardia, JR Diamond, IA Mayer, SJ Isakoff, V Abramson, AN Starodub, J O'Shaughnessy, K Kalinsky, R Moroose, N Shah, D Juric, GI Shapiro, M Guarino, AJ Ocean, WA Messersmith, JD Berlin, WA Wegener, RM Sharkey, DM Goldenberg, LT Vahdat
Institutions: Indiana University Health, Cornell University, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Colorado Cancer Center, Weill Cornell Medicine, Herbert Irving Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Cancer Research
Open Access status: closed
OpenAlex ID: W2593418639
Cites:
Cited by: 1
Related to: 10